R A Koster
Overview
Explore the profile of R A Koster including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
109
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Boonstra J, van der Elst K, Veringa A, Jongedijk E, Bruggemann R, Koster R, et al.
Antimicrob Agents Chemother
. 2017 Oct;
61(12).
PMID: 28971861
The estimated attributable mortality rate for invasive candidiasis (IC) in the intensive care unit (ICU) setting varies from 30 to 40%. Physiological changes in critically ill patients may affect the...
2.
Lambooy S, Bidadkosh A, Nakladal D, van Buiten A, Girgis R, van der Graaf A, et al.
Sci Rep
. 2017 Sep;
7(1):11165.
PMID: 28894214
Diabetic nephropathy is still a common complication of type 2 diabetes mellitus (T2DM) and improvement of endothelial dysfunction (ED) and inhibition of reactive oxygen species (ROS) are considered important targets...
3.
Vu D, Koster R, Bolhuis M, Greijdanus B, Altena R, Nguyen D, et al.
Talanta
. 2014 Mar;
121:9-17.
PMID: 24607103
Introduction: Rifampicin (RIF) and clarithromycin (CLR) are common drugs for the treatment of infections like Mycobacterium tuberculosis and Mycobacterium ulcerans. Treatment for these diseases are long-term and the individual pharmacokinetic...
4.
Vu D, Koster R, Wessels A, Greijdanus B, Alffenaar J, Uges D
J Chromatogr B Analyt Technol Biomed Life Sci
. 2013 Jan;
917-918:1-4.
PMID: 23353809
Clarithromycin and rifampicin are used for the treatment of Mycobacteria. Pharmacokinetic drug interaction is possibly due to the influence of the two drugs on the liver enzymes. Using a Hypurity...
5.
Vu D, Bolhuis M, Koster R, Greijdanus B, de Lange W, van Altena R, et al.
Antimicrob Agents Chemother
. 2012 Aug;
56(11):5758-63.
PMID: 22926568
Linezolid is a promising antimicrobial agent for the treatment of multidrug-resistant tuberculosis (MDR-TB), but its use is limited by toxicity. Therapeutic drug monitoring (TDM) may help to minimize toxicity while...
6.
Vu D, Koster R, Alffenaar J, Brouwers J, Uges D
J Chromatogr B Analyt Technol Biomed Life Sci
. 2011 Apr;
879(15-16):1063-70.
PMID: 21459055
Moxifloxacin (MFX) is a potential oral agent use in the treatment of multidrug-resistance tuberculosis (MDR-TB). Due to variability in pharmacokinetics and in vitro susceptibility of causative bacteria, therapeutic drug monitoring...